




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61F 2/02, A61B 17/11, A61L 31/00		A1	(11) International Publication Number: WO 98/14135
			(43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/US97/16308 (22) International Filing Date: 15 September 1997 (15.09.97) (30) Priority Data: 08/725,916 4 October 1996 (04.10.96) US (71) Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street, S.E., Minneapolis, MN 55455 (US). (72) Inventors: TRANQUILLO, Robert, T.; 2040 Irene Street, Roseville, MN 55113 (US). MOORADIAN, Daniel, L.; 1296 Dunberry Lane, Eagan, MN 55123 (US). GIRTON, Timothy, S.; 41 East County Road C., Little Canada, MN 55117 (US). GUIDO, Stefano; Parco Comola Ricci, 63, I-80122 Naples (IT). (74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).			(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: MAGNETICALLY ORIENTED TISSUE-EQUIVALENT AND BIOPOLYMER RODS

(57) Abstract

Tissue-equivalent and biopolymer tubes and rods include fibrils which are oriented (aligned) by a magnetic field. These oriented fibrils provide enhanced mechanical and cell guidance properties to the tissue-equivalent and biopolymer tubes. One such tissue-equivalent tube includes a body of collagen gel with mammalian tissue cells interspersed therein. The collagen fibrils are circumferentially oriented within the tubular body by a magnetic field, thereby inducing circumferential orientation of the cells. One such biopolymer rod includes collagen fibrils longitudinally oriented along the rod axis by a magnetic field that guides invasion of cells. Methods of making magnetically oriented tissue-equivalent and biopolymer tubes and rods are also disclosed.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MAGNETICALLY ORIENTED TISSUE-EQUIVALENT AND BIOPOLYMER RODS

FIELD OF THE INVENTION

5

This invention relates to oriented tissue-equivalent and biopolymer tubes and in particular bioartificial arteries made of Type I collagen formed into tubes having collagen fibrils circumferentially oriented by a magnetic field. The present invention additionally relates to tissue regeneration structures, and in particular tissue-equivalent and biopolymer rods for nerve regeneration.

10

BACKGROUND OF THE INVENTION

The demand for artificial blood vessels, and in particular, artificial arteries is great. This is due to the fact that over 600,000 surgical procedures involving large and small blood vessels are conducted annually.

15

Arteries are complex structures, as the cellular and extracellular components of the artery wall are not uniformly distributed. Rather, these cellular and extracellular components are organized into discrete layers. These discrete layers have a trilaminant structure of an intima, a media and an adventitia.

20

The mechanical properties of the artery wall are largely due to components of the vessel media layer. Elastin is the most extensible component of the vessel media, whereas collagen is relatively stiff. The presence of smooth muscle cells is important for two reasons. First, the smooth muscle cells synthesize the elastin and collagen present in the vessel media and second, they are capable of contraction and relaxation in response to various external stimuli including vasoactive substances in the blood and sympathetic and parasympathetic nerve impulses. These smooth muscle cells are thus an important source of structural protein that contribute directly to the strength and elasticity of the vessel wall and represent a component of variable elasticity participating in the regulation of vessel tone.

25

30

The elastin and collagen components confer a non-linear stress-strain relationship, in which the elastic modulus of the vessel wall increases (the vessel becomes stiffer) as the vessel is distended. The importance of organization to

mechanical function in the arterial wall is clearly seen when arteries are compared to veins of similar size. In arteries, the circumferentially or (helically) oriented smooth muscle cells and associated elastin and collagen of the media, provide the mechanical strength necessary to withstand the higher pressures that exist in the arterial circulation. In contrast, the media layer of a vein of similar size is reduced in thickness, contains fewer smooth muscle cells, less elastin, and lastly little circumferential orientation of smooth muscle collagen and elastin seen as in the arteries.

Several attempts have been made at creating a completely bioartificial artery. Weinberg and Bell, "A Blood Vessel Model Construction from Collagen and Cultured Vascular Cells" in Science, Vol. 231 (1986), pp. 397-400, reported production of an artery involving smooth muscle cells and fibroblasts in layers of reconstituted Type I collagen that approximate the laminate structure, but not the circumferential orientation of natural arteries. These vessel analogs lacked the mechanical strength necessary to withstand the stress associated with pulsatile blood flow in vivo. To increase the strength, proponents of the Weinberg and Bell approach were forced to reinforce these arteries with synthetic polymer sheaths, such as Dacron®. These bioartificial arteries exhibit a severe drawback in that biocompatibility problems can ultimately lead to graft failure as reported by Langer and Vacanti, "Tissue Engineering" in Science, Vol. 260 (1993), pp. 920-926. Kanada et al., "Mechanical Stress Induced Cellular Orientation and Phenotypic Modulation of 3-D Cultured Smooth Muscle Cells" in ASAIO Journal, (1993), pp. M686-M690, reported a biohybrid vessel which includes polyurethane in order to obtain the appropriate mechanical properties.

The orientation of fibrils and cells in collagen has been studied. For example, Torbet and Ronziere, "Magnetic Alignment of Collagen During Self-Assembly" in Biochem. J., Vol. 219 (1984), pp. 1057-1059, reported collagen fibril orientation in the presence of a magnetic field. Additionally, Guido and Tranquillo, "A Methodology for the Systematic and Quantitative Study of Cell Contact Guidance in Oriented Collagen Gels" in Journal of Cell Science, Vol. 105 (1993), pp. 317-331; reported that cells orient in the same direction as the oriented collagen fibrils, under the phenomenon known as "cell contact guidance".

Despite the study of fibril and cell orientation, there remains the need to provide a tissue-equivalent tube that has mechanical properties that enable it to better withstand distention, typically associated with pulsatile blood flow in arteries, without reinforcing synthetic materials.

5 Additionally, regeneration of severed peripheral nerves commonly
results in permanent damage and disability because mature neurons do not normally
replicate. Once severed, the severed ends of the neurons usually grow in a
misdirected manner, such that they do not reestablish the original connection.
Numerous attempts have been made to reestablish the connections, including the
10 placement of a tube filled with a matrix for bridging the nerve endings. For
Example, Rosen, "Artificial Nerve Graft Using Collagen as an Extracellular Matrix
for Nerve Repair Compared with Suture Autograft in a Rat Model", in Annals of
Plastic Surgery, 25:375-387 (1990) reported slightly inferior nerve regeneration
using tubes filled with collagen gel as compared to nerve autografts, whereas
15 Valentini, et al., "Collagen and Laminin Containing Gels Impede Peripheral Nerve
Regeneration through Semipermeable Nerve Guidance Channels", in Experimental
Neurology, 98:350-356 (1987) reported greatly inferior nerve regeneration as
compared to saline-filled tubes.

20 SUMMARY OF THE INVENTION

The present invention comprises a tissue-equivalent tube that has a cylindrical body made of a reconstituted collagen network with smooth muscle cells interspersed therein. The collagen network is comprised of fibrils that orient circumferentially within the tubular body. The cells are induced by the oriented fibrils to also orient circumferentially. The circumferential orientation of fibrils and cells is characteristic of a native artery and results in improved mechanical properties.

The tissue-equivalent tube is formed by a tubular mold having a central rod and a concentric outer member, aligned to provide a cavity between the central rod and the outer member. The mold includes a longitudinal axis, extending the length of the mold. The cavity is then filled with a solution of collagen and mammalian tissue cells. In one embodiment, the filled tubular mold is then placed

into a high strength magnetic field such that the longitudinal axis of the tubular mold is substantially parallel to the direction of the magnetic field. The magnetic field orients the forming collagen fibrils normal to the direction of the magnetic field, such that the collagen fibrils are oriented circumferentially with respect to the tube.

5 The invention additionally comprises tissue-equivalent and biopolymer rods, along with methods for their manufacture and use. In particular, these tissue-equivalent and biopolymer rods include axially (longitudinally) aligned collagen fibrils that provide a guidance field to exploit the contact response in growth cones at the tips of severed nerve endings (neurite tips) to effectively direct
10 nerve cell growth across the gap between severed nerve endings, regenerating mature nerves.

 The tissue-equivalent rods are formed by using a cylindrical (rod-shaped) mold with a cavity therein, including a longitudinal axis extending the length of the mold and a transverse axis extending the width of the mold. The cavity
15 is then filled with a solution of collagen and mammalian tissue cells, preferably Schwann Cells. In one embodiment, the filled cylindrical mold is then placed into a high strength magnetic field such that the longitudinal axis of the tubular mold is substantially perpendicular to the direction of the magnetic field. The magnetic field aligns (orients) the forming collagen fibrils normal (perpendicular) to the direction
20 of the magnetic field, such that the collagen fibrils are aligned (oriented) substantially parallel to the direction of the longitudinal axis.

 The biopolymer rods are formed by using a cylindrical mold with a cavity therein, including a longitudinal axis extending the length of the mold and a transverse axis extending the width of the mold. The cavity is then filled with a
25 solution of collagen and polymer beads, that include encapsulated neurotrophic factors. In one embodiment, the filled cylindrical mold is then placed into a high strength magnetic field such that the longitudinal axis of the cylindrical mold is substantially perpendicular to the direction of the magnetic field. The magnetic field aligns (orients) the forming collagen fibrils normal (perpendicular) to the direction
30 of the magnetic field, such that the collagen fibrils are aligned (oriented) substantially parallel to the direction of the longitudinal axis.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be described with reference to the accompanying drawings, wherein like reference numerals identify like components.

In the drawings:

5 FIG. 1 is a side view of the tubular mold of the present invention;

FIG. 2 is an illustration of a control tissue-equivalent tube;

FIG. 3 is an illustration of a circumferentially oriented tissue-equivalent tube of the present invention;

10 FIG. 4 is an illustration of an axially oriented biopolymer tube of the present invention;

FIG. 5 is a micrograph of the control tissue-equivalent tube;

FIG. 6 is a micrograph of the circumferentially oriented tissue-equivalent tube of the present invention;

15 FIG. 7 is a chart of a creep test in the circumferential direction on the control tissue-equivalent tube and the circumferentially oriented tissue-equivalent tube of the present invention.

FIG. 8 is a perspective view of a cylindrical mold of the invention;

20 FIG. 9 is a perspective view of the cylindrical mold of the invention having been filled with a collagen solution that is forming collagen fibrils in the presence of a magnetic field (B);

FIG. 10 is a perspective view of an axially aligned biopolymer or tissue-equivalent (collagen gel) rod of the present invention;

FIG. 11a is a perspective view of a severed nerve;

25 FIG. 11b is a perspective view of the axially aligned biopolymer or tissue-equivalent (collagen gel) rod of the present invention being applied to the severed nerve of FIG. 11a;

FIG. 12a is a micrograph of a dorsal root ganglia (DRG) cultured in an aligned biopolymer (collagen gel) rod;

30 FIG. 12b is a micrograph of a dorsal root ganglia cultured in an isotropic biopolymer (collagen gel) rod;

FIG. 13a is a perspective view of a dorsal root ganglia having been placed onto one end of an aligned biopolymer (collagen gel) rod of the present invention;

FIG. 13b is a perspective view of a dorsal root ganglia having been placed onto one end of a non-aligned (isotropic) biopolymer (collagen gel) rod;

FIG. 14a is a birefringence diagram of light intensity (mean gray level) versus rotation (degrees) for the longitudinally aligned (oriented) biopolymer (collagen gel) rod of FIG. 13a of the present invention; and

FIG. 14b is a birefringence diagram of light intensity (mean gray level) versus rotation (degrees) for the isotropic biopolymer (collagen gel) rod of FIG. 13b.

DETAILED DESCRIPTION OF THE INVENTION

As used in the present invention, "tissue-equivalent tubes" or "tissue-equivalent rods" refer to tubes or rods formed of collagen or fibrin and mammalian tissue cells. "Biopolymer tubes" or "biopolymer rods" refer to tubes or rods formed of collagen or fibrin, without the mammalian tissue cells. The term "oriented", refers to the fibrils of the collagen or fibrin, which form the tissue-equivalent or biopolymer tubes, or rods, respectively, being substantially aligned in a specific direction, e.g., axially (along the longitudinal axis of the tube or rod).

The oriented tissue-equivalent tubes of the invention are formed of a solution comprising collagen and mammalian tissue cells, placed into a tubular mold, and subjected to a magnetic field, causing the forming collagen fibrils to become oriented in a direction substantially normal to the direction of the magnetic field. Accordingly, a filled tubular mold placed into the magnetic field, such that its longitudinal axis is parallel to the magnetic field, will have circumferentially oriented fibers, while a filled tubular mold, placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field, will have axially oriented fibrils.

Additionally, biopolymer tubes can be made of pure collagen. Unlike the tissue-equivalent tubes, these biopolymer tubes lack mammalian tissue cells. However, similar to the tissue-equivalent tubes made of the collagen solution

(collagen and mammalian tissue cells), the collagen fibrils orient in the desired direction based upon the positioning of the filled tubular mold with respect to the direction of the magnetic field.

Moreover, tissue-equivalent tubes and biopolymer tubes could be made by the method of the present invention by another tissue matrix material such as fibrin. A fibrin-forming solution, prepared in accordance with conventional methods known in the art, would be placed in a tubular mold and subjected to a magnetic field. As reported by Torbet, "Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures" in Biochemistry, Vol. 25 (1986), pp. 5309-5314, which is incorporated by reference herein, fibrin fibrils, when subjected to a magnetic field, orient in a direction substantially parallel to the direction of the magnetic field. This behavior in the presence of a magnetic field is opposite that of collagen fibrils. Accordingly, a tubular mold formed with fibrin-forming solution, and placed into the magnetic field such that its longitudinal axis is parallel to the magnetic field will have axially oriented fibers, while a filled tubular mold placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field will have circumferentially oriented fibrils.

The collagen referred to above is any monomeric collagen, that self-assembles into fibrils, such as Type I collagen or the like, prepared by any conventional procedures. The mammalian tissue cells referred to above could be grown by any conventional cell growth and culturing method. The tubular molds referred to above could be any mold having a solid rod concentric with an outer member. Both the solid central rod and the outer member are made of materials which will not adhere to the gelled solution, in order that a tube with an open central lumen can be removed.

The present invention envisions molds of single and multiple piece construction. For example, the solid central rod and outer member can be discrete members. In such a case, the outer member is preferably a cylindrical tube. However, rectangular or hexagonal shaped tubes, or the like may also be used. A separate solid rod serves as a second component of the mold. This rod can be formed as a separate member, attached to a plunger (if a syringe barrel forms the outer member) or other portion of the outer member of the mold. The solid rod can

also be formed integral with the plunger. Alternately, a single piece construction, having a formed outer member, bore, barrel, or the like, with an internally positioned axial rod component is permissible. The dimensions and spatial relationships of the outer member and central rod can be varied by one skilled in the art, based on the disclosures herein. Additionally, the tubular mold, or various components thereof, can be made of materials such as Teflon® polyethylene, polypropylene, polyurethane, other equivalent plastic materials, or other non-porous non-magnetic materials.

Turning now to the drawing figures, which show embodiments of the present invention, FIG. 1 shows a tubular mold 20 for making the tissue-equivalent tubes and biopolymer tubes of the invention. The tubular mold 20 is formed from a Teflon® rod 22 and a cylinder 24, preferably formed of a syringe barrel. The Teflon® rod 22 is attached to a plunger 26 at the plunger disc 28. The disc 28 frictionally engages the inner surface 30 of the cylinder 24.

The Teflon® rod 22 is preferably at the center of the cylinder 24. The inner surface 30 of the cylinder 24 and the outer surface 32 of the Teflon® rod 22 are spaced apart such that there is a tubular cavity 34 in the space therebetween. The Teflon® rod 22 is positioned in this manner to provide the resultant tubes 40, 50, 60 (FIGs. 2-4) with a central lumen 44, 54, 64 (FIGs. 2-4) upon removal from the tubular mold 20. The tubular mold 20 includes an opening 35 for receiving the collagen solution and openings 36 for releasing air displaced by the collagen solution. The tubular mold 20 is designed such that a collagen solution injected therein can be easily removed as a collagen tube.

This tubular mold 20 includes a longitudinal axis 38 and a transverse axis 39. These axes 38, 39 will be used to illustrate the directions of fibril orientation.

FIG. 2 shows a tissue-equivalent tube 40, made from the tubular mold 20 of FIG. 1, that is used as a control. The tube 40 has a cylindrical body 42 around a central lumen 44. The body 42 includes randomly oriented collagen fibrils 45 and mammalian tissue cells 46. The tube 40 is formed from a solution of collagen and mammalian tissue cells injected into the tubular mold 20 (FIG. 1) and removed once

the collagen has self-assembled into fibrils 45 entrapping the mammalian tissue cells 46.

The collagen used for this control tube 40 is preferably monomeric Type I collagen, or the like, in a cold (approximately 5°C) neutral solution. The mammalian tissue cells are preferably smooth muscle cells having been grown by conventional cell growth and culture methods, well known to those skilled in the art. The mammalian tissue cells are then dispersed into the cold collagen solution in accordance with the procedure detailed below in Example 1.

The cold solution is then injected into small (pinhole sized) openings 35 in the tubular mold 20. Fibrillogenesis begins as the tubular mold 20 (FIG. 1) is then transferred to a constant temperature box, for incubation in the temperature range of approximately 30°C to 40°C for approximately two hours, during which fibrillogenesis is normally completed. These steps, as well as additional steps required to complete the fabrication of the control tube 40, are described in detail in Example 1, below.

FIG. 3 shows a tissue-equivalent tube 50 of the invention. This tube 50 has a cylindrical body 52 around a central lumen 54. The body 52 includes circumferentially oriented collagen fibrils 55 and mammalian tissue cells 56. The tube 50 includes a longitudinal axis 58 and a transverse axis 59 and is formed from a solution of collagen, including fibrils 55, with mammalian tissue cells 56. The collagen fibrils 55 and mammalian tissue cells 56 of this tube 50 are circumferentially oriented along the transverse axis 59. This circumferential orientation of fibrils 55 and mammalian tissue cells 56 in the tube 50 provides enhanced mechanical strength in the transverse direction, to help prevent it from longitudinal splitting. Additionally, it is believed that the mammalian tissue cells 56, further mechanically strengthen the circumferentially oriented tube 50 by a phenomenon known as "cell traction". This phenomenon of "cell traction" occurs as the mammalian tissue cells 56 place the fibrils 55 in tension while elaborating other reinforcing extracellular matrix molecules, such as elastin, in the collagen, as they differentiate in the tissue-equivalent environment.

The collagen used for the tube 50 of the invention is identical to that described above in reference to the control tube 40 of FIG. 1. The mammalian tissue

cells 56 are preferably smooth muscle cells, identical to those described above in reference to the control tube 40 of FIG. 1.

The solution of collagen and mammalian tissue cells is prepared as described for the control tube 40 of FIG. 1, above (as described in detail in Example 1, below), except that the initiation of fibrillogenesis is substantially simultaneous with the filled tubular mold 20 (FIG. 1) being placed into a high strength (4.7 to 9 Tesla) magnetic field. The magnetic field is preferably a static magnetic field generated by a horizontal bore electromagnet, such as a 4.7 Tesla Model, from the Oxford Company of the United Kingdom. Specifically, the filled tubular mold 20 (FIG. 1) is placed into the magnetic field at an orientation such that its longitudinal axis 38 (FIG. 1) is parallel to the direction of the magnetic field. This incubation, where collagen fibril orientation occurs lasts approximately two hours. These steps are described in detail in Example 2, below.

This positioning of the filled tubular mold 20 (FIG. 1) in the magnetic field causes the growing collagen fibrils 56 to orient circumferentially in the direction of the transverse axis 39 (FIG. 1). The orientation of the fibrils 55 is additionally aided by alteration of the parameters, one parameter being the distance between the outer surface of the Teflon® rod 32 (FIG. 1) and the inner surface of the outer cylinder 30 (FIG. 1). By having a cavity 34 (FIG. 1) with a short distance between the surfaces 30, 32, the orienting effect of the magnetic field in the growing fibrils in the circumferential direction is maximized as the surfaces of the Teflon® rod 22 and the cylinder 24 (FIG. 1) assist in the alignment.

In the present invention, the smooth muscle cells are induced to exhibit circumferential orientation (induced by the circumferentially oriented fibrils described above), similar to that of the smooth muscle cells in the medial layer of an artery. According to the method described herein, this smooth muscle cell orientation contributes to the mechanical properties of the circumferentially oriented tube 50.

The circumferentially oriented tissue-equivalent tubes of the invention are useful as artificial blood vessels, and in particular arteries, as they are reinforced in a circumferential direction, providing additional strength to withstand the distension associated with pulsatile blood flow. However, these oriented tissue-

equivalent tubes, along with tissue-equivalent tubes having fibrils aligned along the longitudinal axis 58 of the tube, known as "axially oriented" (produced by the method detailed in Example 2, below, except that the fibril orienting step is such that the filled mold is placed such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field, during fibrillogenesis), may find use as bioartificial ureters, urethras, tracheas, an esophagus, intestines, and other tubular organs. Sheets of this material could also be produced using sheet molds instead of the tubular molds described above, in order to produce planar structures such as skin or bladders.

Alternately, the cold collagen solution may be kept pure (i.e., without cells) and formed into oriented biopolymer tubes in accordance with the procedures detailed below in Examples 1 and 2. If an axially oriented biopolymer tube formed from this pure cold collagen solution were desired, the orientation step (detailed in Example 2, below), would be such that the filled tubular mold would be placed into the magnetic field such that its longitudinal axis is substantially perpendicular to the direction of the magnetic field. With respect to these tubes, they would be weaker than those with the smooth muscle cells, for the smooth muscles cells enhance the mechanical properties of the tubes.

FIG. 4 shows a biopolymer tube 60 of the invention. This tube 60 has a cylindrical body 62 around a central lumen 64. The body 62 includes fibrin fibrils 65 oriented along the longitudinal axis 68, known as "axially oriented". The tube 60 also has a transverse axis 69. The tube 60 is formed from a fibrin-forming solution including fibrinogen and thrombin, prepared in accordance with that described in Torbet, "Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures" in Biochemistry, Vol. 25 (1986), pp. 5309-5314. This fibrin-forming solution is then made into an axially oriented biopolymer tube in accordance with Examples 1 and 2 below. However, should a tissue-equivalent tube with circumferentially oriented fibrin fibrils (oriented along the transverse axis 69) be desired, the orientation step would be opposite that disclosed in Example 2 below, as the filled tubular mold 20 (FIG. 1) would be placed into the magnetic field such that its longitudinal axis 68 is perpendicular to the direction of the magnetic field.

These axially oriented fibrin tubes, as well as axially oriented collagen biopolymer tubes (discussed above) are particularly useful as nerve regeneration conduits. This is due to the fact that the axially oriented fibrils 65 can serve to guide the inward growth and movement of host neurons 70 at opposite ends of the tube 60, such that the neurons at each end ultimately grow together. Rejoining of the severed nerve would occur in less time as compared to a randomly oriented biopolymer tube.

Turning now to FIGs. 5 and 6, there are shown micrographs of a control tissue-equivalent tube (FIG. 5) and a circumferentially oriented tissue-equivalent tube (FIG. 6), produced in accordance with the invention, as detailed in Examples 1 and 2 below. In FIGs. 5 and 6, the horizontal dimension is coincident with the longitudinal direction of the tube and the vertical dimension is coincident with the circumferential (transverse) direction of the tube. In FIG. 5, the cells appear randomly oriented in this control tube, while in FIG. 6, the cells appear circumferentially oriented.

Turning now to FIGs. 8 and 9, there is shown a cylindrical mold 120 for making the tissue-equivalent and biopolymer rods 130 (FIG. 10) of the present invention. These tissue-equivalent and biopolymer rods 130 are manufactured similarly, with the differences in the manufacturing steps noted below.

The cylindrical mold 120 for making these tissue-equivalent and biopolymer rods 130 is preferably formed of a TEFLON® cylinder 122 (preferably approximately 15 mm in length) having a cavity (lumen) 123, preferably of a diameter corresponding to that of a peripheral nerve (approximately 0.5-2mm). The ends of the cylinder 122 receive plugs 124, 125. Alternately, biodegradable or bioresorbable polymer cylinders may be used as the cylindrical mold 120.

A first plug 124 is initially pushed into the cylinder 122 for the mold to receive collagen solution (made in accordance with the solutions described herein), preferably by injection from a syringe 126. Once the cavity (lumen) 123 is filled, the second plug 125 is fitted into the cylinder 122. The cylindrical mold 120 is designed such that the collagen solution injected therein can be easily removed as a collagen gel rod. Alternately, if the biodegradable or bioresorbable cylinder is used

as the cylindrical mold, the collagen gel rod is not removed from the biodegradable or bioresorbable cylinder.

This cylindrical mold 120 includes a longitudinal axis 128 and a transverse axis 129. These axes 128, 129 will be used to illustrate the directions of fibril alignment (orientation) in the resultant tissue-equivalent and biopolymer rods.

The collagen used for these tissue-equivalent or biopolymer rods is preferably monomeric Type I collagen, or the like, in a cold (approximately 5°C) neutral solution, prepared in accordance with Example 1 below. If a tissue-equivalent rod is desired, the solution includes mammalian tissue cells, that are preferably Schwann Cells and/or fibroblasts/endothelial cells, having been grown by conventional cell growth and culture methods, well known to those skilled in the art. The mammalian tissue cells are then dispersed into the cold collagen solution in accordance with the procedure detailed below in Example 1, except that the smooth muscle cells (mammalian tissue cells of Example 1) are substituted with Schwann Cells and/or fibroblasts/endothelial cells.

Alternately, if a biopolymer rod is desired, in a preferred step, small (approximately 10-15 micrometer diameter) biodegradable/bioresorbable polymer beads with encapsulated neurotrophic factors (such as nerve growth factor) are added to the cold collagen neutral solution. These biodegradable/bioresorbable polymer beads would be added to the collagen solution similar to the mammalian tissue cells, in accordance with Example 1 below. The polymer beads would function similar to the Schwann cells, of the tissue-equivalent rods, by releasing the encapsulated neurotropic factor(s) that serve as an additional stimulus for neural growth (e.g., neurite elongation).

The cold solution is then injected from the syringe 126 into the cavity 123 of the cylindrical mold 120. Injection of the solution is preferably done slowly to avoid formation of air bubbles or air pockets. In accordance with Example 2, as detailed below, fibrillogenesis begins as the filled cylindrical mold 120 (FIG. 9) is then transferred to a constant temperature box, for incubation in the temperature range of approximately 30°C to 40°C, and is placed in a high strength (preferably at least 4 Tesla) magnetic field, as described above and in Examples 1 and 2 below, with the longitudinal axis 128 oriented substantially perpendicular to the direction of

the magnetic field (B) (indicated by arrows 132), for approximately two hours. Additional detail for performing these steps is provided in Examples 1 and 2 below, except that the tissue-equivalent and biopolymer rods of the invention are subject to fibrillogenesis (collagen fibril self assembly) in the presence of a magnetic field.

5 Upon removal from the magnetic field, the now-formed tissue-equivalent and biopolymer rods are removed from the TEFLON® cylindrical molds, by allowing the rods to slide out of the molds. If the molds are formed of biodegradable or bioresorbable polymer cylinders, these cylinders are preferably not removed, and remain as part of the rod for subsequent use. The resultant rods may
10 be subject to further processing by steps similar to those described in Example 2 below.

FIG. 10 shows a tissue-equivalent or biopolymer rod 130, made from the cylindrical mold 120. (The mammalian tissue cells of the tissue-equivalent rod and the polymer beads of the biopolymer rod are too small to be observed in this
15 drawing figure.) The tissue-equivalent or biopolymer rod 130 preferably includes a cylindrical body 134 with longitudinally aligned (oriented) collagen fibrils 135, in the direction of the longitudinal axis 128. (In this drawing figure, the cylindrical mold 120, if a TEFLON® cylinder, has been removed.)

As stated above, one use of the tissue-equivalent rods and biopolymer
20 rods 130 of the invention is for peripheral nerve regeneration. As shown in FIGs. 11a and 11b, there is a severed nerve 140 having a gap 142 between its severed ends 144, 145. The tissue-equivalent or biopolymer rod 130 is placed in the gap 142, and connected to each of the severed nerve ends 144, 145, for example, by sutures 146, 147. The tissue-equivalent or biopolymer rod 130 comprised of longitudinally
25 aligned (oriented) collagen fibrils serves to guide neural growth across the gap between the severed nerve endings, thereby promoting regeneration of the original neural connection. This process has been simulated with a Dorsal Root Ganglia (DRG) from a chick embryo, and is detailed below in Examples 4-6.

Tissue-equivalent rods and biopolymer rods of fibrin may also be
30 made in accordance with the invention. These tissue-equivalent and biopolymer rods have a cylindrical body, that includes fibrin fibrils oriented along the longitudinal axis (the longitudinal axis defined in accordance with FIGs. 8-10

above), known as "axially oriented". The rods is formed from a fibrin-forming solution including fibrinogen and thrombin, prepared in accordance with that described in Torbet, "Fibrin Assembly in Human Plasma and Fibrinogen/Albumin Mixtures" in Biochemistry, Vol. 25 (1986), pp. 5309-5314. In the case of tissue-equivalent fibrin rods, mammalian tissue cells (i.e., Schwann Cells and/or fibroblasts/endothelial cells) may be added to the fibrin-forming solution in accordance with the preparations discussed above. In the case of biopolymer fibrin rods, polymer beads (as discussed above), may be added to the fibrin-forming solution in accordance with the preparations discussed above. These fibrin-forming solutions are then placed into a cylindrical mold (of a TEFLON® cylinder, or a bioresorbable or biodegradable material cylinder) and made into an axially oriented biopolymer rod (with the resultant fibrils aligned in the direction of the longitudinal axis) in accordance with Examples 1 and 2 below (such that the cylindrical molds are placed into the magnetic field parallel to the direction of the magnetic field).

15

EXAMPLE 1

The control tube of FIG. 5 is prepared as follows. 20 microliters of cold (5°C) HEPES Buffer Solution (1M) (No. 4573, The Merk Index, 11th ed.) are mixed with 50 microliters 10x Gibco Minimum Essential Medium (MEM) (Gibco BRL, Gaithersburg, Maryland 20877) in a disposable 15ml sterile vial. 132 microliters of room temperature NaOH (0.1N) is then added to the HEPES-MEM solution.

A solution is then prepared as 60 microliters of Fetal Bovine Serum (FBS) from Hyclone Laboratories, Inc., Logan, Utah 84321, 1 microliter of Penicillin-Streptomycin solution (5000 units of Penicillin and 5000 micrograms Streptomycin per millimeter in 0.85% saline solution) (Pen-Strep), and 10 microliters L-Glutamate solution (29.2 milligrams per milliliter) in 0.85% saline solution) are obtained from separate stocks, and each is frozen -20°C. The separate FBS, Pen-Strep, and L-Glutamate are warmed to room temperature and individually added to the 15ml vial.

30

677 microliters of cold (5°C) Vitrogen® 100 Collagen, available from Celtrix Pharmaceuticals, Inc., 3055 Patrick Henry Drive, Santa Clara, California 95054, are then added and the solution is gently mixed with a pipette.

A cold (5°C) cell suspension of smooth muscle cells (approximately
5 4×10^6 cells/ml) suspended in 50 microliters Gibco Medium 199 (M-199) (Gibco BRL, Gaithersburg, Maryland 20877) is prepared. The solution includes rat aortic smooth muscle cells prepared in accordance with the method disclosed in Diglio, et al., "Rat Cerebral Microvascular Smooth Muscle Cells in Culture" in J. Cell. Physiol., Vol. 129(2) (1986), pp. 131-141, which is incorporated by reference herein.
10 The cells were maintained in Gibco Dulbecco's Modified Eagle Medium (DMEM) (Gibco BRL, Gaithersburg, Maryland 20877) containing 10% Fetal Bovine Serum (FBS) and were subcultured twice weekly. Only cells below passage 25 that retain the phenotypic traits of expressing smooth muscle cell specific alpha-actin and myosin, and not the Factor VIII-related antigen were used here. This cold cell
15 suspension is now added to the 15ml vial.

The contents of the 15ml vial are gently mixed with a pipette. The solution is kept on ice all the while. The cell and collagen solution is syringed out using standard sterile 3 milliliter syringes and is injected into a sterile mold. The mold was previously sterilized by soaking in 70% ethanol and followed by repeated
20 rinsing with sterile water. The opening on the mold to inject the solution is covered with Parafilm® (American National Can Company, Chicago, Illinois) and the mold is placed on ice. The mold has an outer diameter of 1.2 centimeters and an inner diameter (for the central solid rod) of 0.635 centimeters, and a length of 1.2 centimeters. The process is repeated until the desired amount of molds are full. The
25 molds are then placed in an incubator at 32°C for two hours (the fibrillogenesis period).

EXAMPLE 2

The tubes of FIG. 6 were initially prepared in accordance with
30 Example 1 above, except that the mold(s) once full are not placed in an incubator at 32°C for the two hour fibrillogenesis period. Rather, the air and water tight molds are taken to a 4.7 Tesla magnet (Oxford Company, United Kingdom) on ice, and

once there they are removed from the ice bath and placed in 1.25 inch thick styrofoam boxes filled with water at 32°C. The molds are submerged in the water. The styrofoam box, containing the submerged molds, is then placed in a plastic bag and slid into the bore of the magnet, where the collagen solution in the molds is left to self-assemble for 2 hours (the fibrillogenesis period). In order to minimize gravity-induced cell settling during fibrillogenesis, the molds are briefly removed from the magnet and carefully rotated 180° and returned to the magnet. This procedure is done at 10 minute intervals.

When the two hours are up, the molds are removed from the magnet. Immediately, in a sterile hood, the molds are opened and the tissue-equivalent tubes are removed and placed in sterile 30 milliliter glass vials filled with 20 milliliters of M-199 cell culture medium supplemented with 5% (by volume) L-Glutamine, 5% (by volume) Fungizone® (E. R. Squibb & Sons, Inc., New York, New York) (250 micrograms amphotericin B and 205 micrograms sodium deoxytcholate/milliliter in sterile/distilled water), 5% (by volume) Penicillin-Streptomycin solution (5000 units of Penicillin and 5000 micrograms streptomycin per milliliter in 0.85% saline solution), and 10% (by volume) Hyclone Fetal Bovine Serum. Smaller (1/8 inch) diameter sterile Teflon® rods are placed in the lumens of the tubes and they are subsequently placed in an incubator at 37°C for extended periods of time (as long as is desired). The M-199 cell culture medium with supplements (described above) in the 30ml glass vials is replaced at two day intervals.

EXAMPLE 3

The control tissue-equivalent tube (FIG. 5) and the circumferentially oriented tissue-equivalent tube (FIG. 6) were both subsequently cultured in an incubator at 37°C for 108 hours and then tested on a Liveco Vitrodyne® 200, available from Liveco, Inc. of Burlington, Vermont. The testing procedure involved first, slowly extending the tubes to a collapsed state and then allowing the tubes time to equilibrate before testing. This testing mode simulated distension in an artery. Creep compliance was measured over time and the results are plotted in FIG. 7. The circumferentially oriented tissue-equivalent tube response is line 100 while the unoriented (control) tissue-equivalent tube response is line 102. Based on these

responses, the circumferentially oriented tube showed less instantaneous creep, as it was stiffer (less elastic) than the unoriented (control) tube. The creep rate at longer times is also somewhat less for the oriented tube (FIG. 6), indicating that it is also more viscous.

5

EXAMPLE 4

Dorsal Root Ganglia (DRG) was explanted from a day 12 chick embryo and cultured (by direct entrapment) into an aligned biopolymer (collagen gel) rod, prepared in accordance with the above described methods for producing biopolymer rods of the present invention, except polymer beads (as described above) were not included. As illustrated in the micrograph of FIG. 12a, taken two days after the culture, the aligned biopolymer collagen gel rod 150a (having fibrils aligned in the direction of the arrow 151) showed neurites 152a that elongated from the DRG 154a in the same direction as the fibril alignment (orientation). The neurites were imaged by antibody staining (anti-neurofilament 200 KD).

15

EXAMPLE 5

Dorsal Root Ganglia (DRG) was explanted and cultured by direct entrapment from a day 12 chick embryo into an isotropic (non-aligned fibril) biopolymer (collagen gel) rod. The isotropic biopolymer (collagen gel) rod was prepared by the method described in Example 1. As illustrated by the micrograph of FIG. 12b, taken two days after the culture, the isotropic biopolymer (collagen gel) rod 150b showed neurites 152b that elongated randomly from the DRG 154b. The neurites were imaged by antibody staining (anti-neurofilament 200 KD).

20

EXAMPLE 6

A magnetically oriented biopolymer (collagen gel) rod was produced in accordance with the present invention, except polymer beads (as described above) were not included. An invasion assay was prepared as Dorsal Root Ganglia (DRG) was explanted from a day 12 chick embryo and placed on one flat end of the rod and incubated for two days for the case of a magnetically oriented rod, prepared in a 4.7 Tesla magnetic field (FIG. 13a). In FIGs. 13a and 13b, as seen along the

30

longitudinal axes of the biopolymer (collagen gel) rods 162a, 162b the neurites from the DRG 164a, 164b have advanced from their respective neurite origins 166a, 166b. The leading edge of the DRG neurite front 168a in the aligned biopolymer rod 162a (having fibrils aligned in the direction of the arrow 163) has advanced further than
5 the leading edge 168b of the DRG neurite front in the isotropic rod 162b (having non-aligned fibrils).

To confirm that the neurite advancement was due to magnetically aligned (oriented) collagen, the rods were analyzed in polarized light. As shown in FIG. 14a, the rod prepared in the 4.7 Tesla magnetic field exhibited strong
10 birefringence (47×10^{-6}), indicative of highly aligned collagen fibrils, whereas little or no birefringence was measured for the non-aligned fibril control (isotropic) rod, as shown in FIG. 14b.

While the invention has been described in connection with several embodiments, it will be understood that the invention is not limited to these
15 embodiments. The invention is intended to cover all alternatives, modifications and equivalents as may be included within the spirit and scope thereof, as defined by the appended claims.

What is claimed is:

1. A method of forming a tissue-equivalent rod comprising:
providing a mold extending in the longitudinal and transverse directions, the mold including a cavity, the mold including an axis extending in the longitudinal direction;
filling the cavity of the mold with a solution comprising collagen and mammalian tissues cells; and
placing the filled mold into a magnetic field, such that the longitudinal axis of the mold is substantially perpendicular to the direction of the magnetic field, whereby the fibrils forming in the collagen align in the longitudinal direction.
2. The method of claim 1, wherein the mold is cylindrical in shape.
3. The method of claim 1, wherein the collagen is monomeric Type I collagen.
4. The method of claim 1, wherein the filling step involves injecting the solution of collagen and cells.
5. The method of claim 1, wherein the mammalian tissue cells are Schwann cells.
6. The method of claim 1, wherein the magnetic field is a static magnetic field.
7. The method of claim 1, wherein the mold includes a biodegradable or bioresorbable polymer cylinder.
8. The method of claim 1, additionally comprising:
removing the filled mold from the magnetic field; and
removing the mold from the formed tissue-equivalent rod.
9. A tissue-equivalent rod, the rod including a cylindrical body including a longitudinal axis, the body comprising collagen and mammalian tissue cells

interspersed within the collagen, the collagen including fibrils, the fibrils aligned in a direction substantially along the longitudinal axis within the body.

10. The tissue-equivalent rod of claim 9, wherein the collagen is monomeric Type I collagen.

11. The tissue-equivalent rod of claim 9, wherein the mammalian tissue cells include Schwann cells.

12. The tissue-equivalent rod of claim 9, additionally comprising an outer casing including a biodegradable or bioresorbable polymer cylinder.

13. A method for promoting nerve regeneration comprising:
providing a tissue-equivalent rod having longitudinal and traverse dimensions and first and second ends, the rod being cylindrical and of a predetermined circumference, the rod having a body comprising collagen and mammalian tissue cells interspersed within the collagen, the collagen including fibrils, the fibrils aligning and extending substantially in the longitudinal dimension;
positioning said tissue-equivalent rod intermediate a first nerve ending and a second nerve ending; said first and second nerve ending formed by the severance of a nerve; and
attaching said first end of said tissue-equivalent tube to said first nerve ending and said second end of said tissue-equivalent tube to said second nerve ending.

14. The method of claim 13, wherein said tissue-equivalent rod additionally comprises an outer casing including a biodegradable or bioresorbable polymer cylinder.

15. A method of forming a biopolymer rod comprising:

providing a mold extending in the longitudinal and transverse directions, the mold including a cavity, the mold including an axis extending in the longitudinal direction;

filing the cavity of the mold with a solution comprising collagen and polymer beads; and

placing the filled mold into a magnetic field, such that the longitudinal axis of the mold is substantially perpendicular to the direction of the magnetic field, whereby the fibrils forming in the collagen align in the longitudinal direction.

16. The method of claim 15, wherein the mold is cylindrical in shape.
17. The method of claim 15, wherein the collagen is monomeric Type I collagen.
18. The method of claim 15, wherein the filling step involves injecting the solution of collagen and polymer beads.
19. The method of claim 18, wherein said polymer beads include at least one neurotrophic factor.
20. The method of claim 19, wherein said at least one neurotrophic factor is releasably encapsulated within said polymer beads, such that said at least one neurotrophic factor is released from said polymer beads into said biopolymer rod.
21. The method of claim 15, wherein the magnetic field is a static magnetic field.
22. The method of claim 15, wherein the mold includes a biodegradable or bioresorbable polymer cylinder.
23. The method of claim 15, additionally comprising:
removing the filled mold from the magnetic field; and
removing the mold from the formed biopolymer rod.

24. A biopolymer rod, the rod including a cylindrical body including a longitudinal axis, the body comprising collagen and polymer beads interspersed within the collagen, the collagen including fibrils, the fibrils aligned in a direction substantially parallel to the longitudinal axis.
25. The biopolymer rod of claim 24, wherein the collagen is monomeric Type I collagen.
26. The biopolymer rod of claim 24, additionally comprising an outer casing including a biodegradable or bioresorbable polymer cylinder.
27. biopolymer rod of claim 24, wherein said polymer beads include at least one neurotrophic factor.
28. The biopolymer rod of claim 27, wherein said at least one neurotrophic factor is releasably encapsulated within said polymer beads, such that said at least one neurotrophic factor is released from said polymer beads into said biopolymer rod.
29. A method for providing nerve regeneration comprising:
providing a biopolymer rod having longitudinal and traverse dimensions and first and second ends, the rod including a body comprising collagen and polymer beads interspersed within the collagen, the collagen including fibrils, the fibrils being aligned and extending substantially in the longitudinal dimension;
positioning said biopolymer rod intermediate a first nerve ending and a second nerve ending, said first and second nerve endings formed by the severance of a nerve; and
attaching said first end of said biopolymer rod tube to said first nerve ending and said second end of said biopolymer rod to said second nerve ending.
30. The method of claim 29, wherein said biopolymer rod additionally comprises an outer casing including a biodegradable or bioresorbable polymer cylinder.

31. The method of claim 29, wherein said polymer beads include at least one neurotrophic factor.

32. The method of claim 31, wherein said at least one neurotrophic factor is releasably encapsulated within said polymer beads, such that said at least one neurotrophic factor is released from said polymer beads into said biopolymer rod.

AMENDED CLAIMS

[received by the International Bureau on 17 February 1998 (17.02.98)];
original claims 1,2,7,9 and 27 amended; remaining
claims unchanged (3 pages)]

1. A method of forming a tissue-equivalent rod comprising:
providing a rod-shaped mold extending in the longitudinal and transverse directions, the mold including a cavity, the mold including an axis extending in the longitudinal direction;
filling the cavity of the mold with a solution comprising collagen and mammalian tissues cells; and
placing the filled mold into a magnetic field, such that the longitudinal axis of the mold is substantially perpendicular to the direction of the magnetic field, whereby the fibrils forming in the collagen align in the longitudinal direction.
2. The method of claim 1, wherein the rod-shaped mold is cylindrical.
3. The method of claim 1, wherein the collagen is monomeric Type I collagen.
4. The method of claim 1, wherein the filling step involves injecting the solution of collagen and cells.
5. The method of claim 1, wherein the mammalian tissue cells are Schwann cells.
6. The method of claim 1, wherein the magnetic field is a static magnetic field.
7. The method of claim 1, wherein the rod-shaped mold includes a biodegradable or bioresorbable polymer outer casing.
8. The method of claim 1, additionally comprising:
removing the filled mold from the magnetic field; and
removing the mold from the formed tissue-equivalent rod.
9. A tissue-equivalent rod, the rod including a cylindrical body including a longitudinal axis, the body extending along the longitudinal axis and comprising

collagen and mammalian tissue cells interspersed within the collagen, the collagen including fibrils, the fibrils aligned in a direction substantially parallel to the longitudinal axis within the body.

10. The tissue-equivalent rod of claim 9, wherein the collagen is monomeric Type I collagen.

11. The tissue-equivalent rod of claim 9, wherein the mammalian tissue cells include Schwann cells.

12. The tissue-equivalent rod of claim 9, additionally comprising an outer casing including a biodegradable or bioresorbable polymer cylinder.

13. A method for promoting nerve regeneration comprising:
providing a tissue-equivalent rod having longitudinal and traverse dimensions and first and second ends, the rod being cylindrical and of a predetermined circumference, the rod having a body comprising collagen and mammalian tissue cells interspersed within the collagen, the collagen including fibrils, the fibrils aligning and extending substantially in the longitudinal dimension;
positioning said tissue-equivalent rod intermediate a first nerve ending and a second nerve ending; said first and second nerve ending formed by the severance of a nerve; and
attaching said first end of said tissue-equivalent tube to said first nerve ending and said second end of said tissue-equivalent tube to said second nerve ending.

14. The method of claim 13, wherein said tissue-equivalent rod additionally comprises an outer casing including a biodegradable or bioresorbable polymer cylinder.

15. A method of forming a biopolymer rod comprising:

24. A biopolymer rod, the rod including a cylindrical body including a longitudinal axis, the body comprising collagen and polymer beads interspersed within the collagen, the collagen including fibrils, the fibrils aligned in a direction substantially parallel to the longitudinal axis.
25. The biopolymer rod of claim 24, wherein the collagen is monomeric Type I collagen.
26. The biopolymer rod of claim 24, additionally comprising an outer casing including a biodegradable or bioresorbable polymer cylinder.
27. The biopolymer rod of claim 24, wherein said polymer beads include at least one neurotrophic factor.
28. The biopolymer rod of claim 27, wherein said at least one neurotrophic factor is releasably encapsulated within said polymer beads, such that said at least one neurotrophic factor is released from said polymer beads into said biopolymer rod.
29. A method for providing nerve regeneration comprising:
providing a biopolymer rod having longitudinal and traverse dimensions and first and second ends, the rod including a body comprising collagen and polymer beads interspersed within the collagen, the collagen including fibrils, the fibrils being aligned and extending substantially in the longitudinal dimension;
positioning said biopolymer rod intermediate a first nerve ending and a second nerve ending, said first and second nerve endings formed by the severance of a nerve; and
attaching said first end of said biopolymer rod tube to said first nerve ending and said second end of said biopolymer rod to said second nerve ending.
30. The method of claim 29, wherein said biopolymer rod additionally comprises an outer casing including a biodegradable or bioresorbable polymer cylinder.




FIG. 1

2/10




FIG. 2




FIG. 3




FIG. 4

3/10

FIG. 5





FIG. 6



4/10




FIG. 7

5/10

FIG. 8





FIG. 9



6/10

FIG. 10




FIG. 11a





FIG. 11b






Fig 12a




Fig 12b

9/10




Fig 13b

Fig 13a

10/10

FIG. 14a





FIG. 14b



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/16308

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61F2/02 A61B17/11 A61L31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F A61B A61L A23J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A Y	WO 89 10728 A (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 16 November 1989 see page 17, line 20 - page 18, line 15 ---	1, 15 9-12, 24-26
A Y	WO 95 20359 A (INSTITUTE OF MOLECULAR BIOLOGY) 3 August 1995 see abstract; claims 18, 19; figures ---	1, 15 9-12, 24-26
A	US 3 114 372 A (GRISSET) 17 December 1963 ---	
A	WO 93 24155 A (LIESI) 9 December 1993 ---	
A	US 4 863 668 A (GRIFFITHS) 5 September 1989 ---	
A	US 4 018 906 A (OSTENDORF) 19 April 1977 -----	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

11 December 1997

Date of mailing of the international search report

22.12.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Steenbakker, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/16308

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13 14 29-32
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39:1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/16308

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8910728 A	16-11-89	US 4955893 A	11-09-90
WO 9520359 A	03-08-95	US 5656605 A	12-08-97
		AU 1732295 A	15-08-95
US 3114372 A	17-12-63	BE 638910 A	
		CH 452116 A	
		FR 1409722 A	08-12-65
		GB 1019711 A	
		GB 1019712 A	
		NL 283966 A	
		US 3114593 A	17-12-63
WO 9324155 A	09-12-93	AU 4072393 A	30-12-93
US 4863668 A	05-09-89	NONE	
US 4018906 A	19-04-77	NONE	